Oxycodone conversion reference
Check OpioidCalc's OME factors by route, then open the formulation-specific pharmacology, cautions and supporting sources.
Educational reference for qualified healthcare professionals. Conversion factors estimate oral morphine equivalent daily dose. They are not a recommended switching dose. Confirm the result with a current source and local guidance.
Free download · iOS and Android · Optional Pro features
Current OpioidCalc factors
Multiply the dose or delivery rate in the stated units by the factor to estimate mg oral morphine equivalent per day. These are the factors currently used by OpioidCalc. Methadone uses 4.7 when converting methadone to OME.
| Route | Input units | OME factor |
|---|---|---|
| Oral | mg/day | 1.5 |
| Parenteral | mg/day | 3 |
| Rectal | mg/day | 1.5 |
Compare a complete regimen in the app
Formulations and cautions
Choose a formulation to read its pharmacology, population, limitations and source references.
OralDefault in appImmediate-release tablet
App source review: 27 August 2026
View details and sources
Immediate-release tablet
App source review: 27 August 2026
View details and sources- Peak concentration or effect
- Approximately 1.25 to 2.6 hours across the cited tablet and solution studies
Population: Adults described in the cited product information
Applicability: United States
- Limitation: Product-specific evidence; do not transfer to other formulations.
- Oxycodone hydrochloride immediate-release tablet prescribing information12.3 Pharmacokinetics. United States. Source revised 7 August 2026. App review 27 August 2026. Regulatory product information.
- Elimination half-life
- Approximately 2.9 to 4 hours across the cited tablet and solution studies
Population: Adults described in the cited product information
Applicability: United States
- Limitation: Product-specific evidence; do not transfer to other formulations.
- Oxycodone hydrochloride immediate-release tablet prescribing information12.3 Pharmacokinetics. United States. Source revised 7 August 2026. App review 27 August 2026. Regulatory product information.
- Steady state
- 18 to 24 hours
Population: Adults described in the cited product information
Applicability: United States
- Limitation: Product-specific evidence; do not transfer to other formulations.
- Oxycodone hydrochloride immediate-release tablet prescribing information12.3 Pharmacokinetics. United States. Source revised 7 August 2026. App review 27 August 2026. Regulatory product information.
- Bioavailability
- 60% to 87%
Population: Adults described in the cited product information
Applicability: United States
- Limitation: Product-specific evidence; do not transfer to other formulations.
- Oxycodone hydrochloride immediate-release tablet prescribing information12.3 Pharmacokinetics. United States. Source revised 7 August 2026. App review 27 August 2026. Regulatory product information.
- Receptor activity
- Full mu-opioid receptor agonist.
Population: Adults described in the cited product information
Applicability: United States
- Limitation: Product-specific evidence; do not transfer to other formulations.
- Oxycodone hydrochloride immediate-release tablet prescribing information12.1 Mechanism of Action. United States. Source revised 7 August 2026. App review 27 August 2026. Regulatory product information.
- Metabolism
- CYP3A4 forms noroxycodone; CYP2D6 forms oxymorphone.
Population: Adults described in the cited product information
Applicability: United States
- Limitation: Product-specific evidence; do not transfer to other formulations.
- Oxycodone hydrochloride immediate-release tablet prescribing information12.3 Pharmacokinetics. United States. Source revised 7 August 2026. App review 27 August 2026. Regulatory product information.
- Active metabolites
- Oxymorphone is active, but its contribution after oxycodone is considered clinically insignificant by the label.
Population: Adults described in the cited product information
Applicability: United States
- Limitation: Product-specific evidence; do not transfer to other formulations.
- Oxycodone hydrochloride immediate-release tablet prescribing information12.3 Pharmacokinetics. United States. Source revised 7 August 2026. App review 27 August 2026. Regulatory product information.
- Elimination
- Oxycodone and metabolites are eliminated primarily in urine.
Population: Adults described in the cited product information
Applicability: United States
- Limitation: Product-specific evidence; do not transfer to other formulations.
- Oxycodone hydrochloride immediate-release tablet prescribing information12.3 Pharmacokinetics. United States. Source revised 7 August 2026. App review 27 August 2026. Regulatory product information.
- Renal impairment
- Renal dysfunction increases oxycodone exposure and requires additional caution.
Population: Adults described in the cited product information
Applicability: United States
- Limitation: Product-specific evidence; do not transfer to other formulations.
- Oxycodone hydrochloride immediate-release tablet prescribing information8.7 Renal Impairment. United States. Source revised 7 August 2026. App review 27 August 2026. Regulatory product information.
- Hepatic impairment
- Hepatic dysfunction can substantially increase oxycodone exposure.
Population: Adults described in the cited product information
Applicability: United States
- Limitation: Product-specific evidence; do not transfer to other formulations.
- Oxycodone hydrochloride immediate-release tablet prescribing information8.6 Hepatic Impairment. United States. Source revised 7 August 2026. App review 27 August 2026. Regulatory product information.
OralImmediate-release oral solution
App source review: 27 August 2026
View details and sources
Immediate-release oral solution
App source review: 27 August 2026
View details and sources- Peak concentration or effect
- Approximately 1.25 to 2.6 hours across the cited tablet and solution studies
Population: Adults described in the cited product information
Applicability: United States
- Limitation: Product-specific evidence; do not transfer to other formulations.
- Oxycodone hydrochloride immediate-release tablet prescribing information12.3 Pharmacokinetics. United States. Source revised 7 August 2026. App review 27 August 2026. Regulatory product information.
- Elimination half-life
- Approximately 2.9 to 4 hours across the cited tablet and solution studies
Population: Adults described in the cited product information
Applicability: United States
- Limitation: Product-specific evidence; do not transfer to other formulations.
- Oxycodone hydrochloride immediate-release tablet prescribing information12.3 Pharmacokinetics. United States. Source revised 7 August 2026. App review 27 August 2026. Regulatory product information.
- Steady state
- 18 to 24 hours
Population: Adults described in the cited product information
Applicability: United States
- Limitation: Product-specific evidence; do not transfer to other formulations.
- Oxycodone hydrochloride immediate-release tablet prescribing information12.3 Pharmacokinetics. United States. Source revised 7 August 2026. App review 27 August 2026. Regulatory product information.
- Bioavailability
- 60% to 87%
Population: Adults described in the cited product information
Applicability: United States
- Limitation: Product-specific evidence; do not transfer to other formulations.
- Oxycodone hydrochloride immediate-release tablet prescribing information12.3 Pharmacokinetics. United States. Source revised 7 August 2026. App review 27 August 2026. Regulatory product information.
- Receptor activity
- Full mu-opioid receptor agonist.
Population: Adults described in the cited product information
Applicability: United States
- Limitation: Product-specific evidence; do not transfer to other formulations.
- Oxycodone hydrochloride immediate-release tablet prescribing information12.1 Mechanism of Action. United States. Source revised 7 August 2026. App review 27 August 2026. Regulatory product information.
- Metabolism
- CYP3A4 forms noroxycodone; CYP2D6 forms oxymorphone.
Population: Adults described in the cited product information
Applicability: United States
- Limitation: Product-specific evidence; do not transfer to other formulations.
- Oxycodone hydrochloride immediate-release tablet prescribing information12.3 Pharmacokinetics. United States. Source revised 7 August 2026. App review 27 August 2026. Regulatory product information.
- Active metabolites
- Oxymorphone is active, but its contribution after oxycodone is considered clinically insignificant by the label.
Population: Adults described in the cited product information
Applicability: United States
- Limitation: Product-specific evidence; do not transfer to other formulations.
- Oxycodone hydrochloride immediate-release tablet prescribing information12.3 Pharmacokinetics. United States. Source revised 7 August 2026. App review 27 August 2026. Regulatory product information.
- Elimination
- Oxycodone and metabolites are eliminated primarily in urine.
Population: Adults described in the cited product information
Applicability: United States
- Limitation: Product-specific evidence; do not transfer to other formulations.
- Oxycodone hydrochloride immediate-release tablet prescribing information12.3 Pharmacokinetics. United States. Source revised 7 August 2026. App review 27 August 2026. Regulatory product information.
- Renal impairment
- Renal dysfunction increases oxycodone exposure and requires additional caution.
Population: Adults described in the cited product information
Applicability: United States
- Limitation: Product-specific evidence; do not transfer to other formulations.
- Oxycodone hydrochloride immediate-release tablet prescribing information8.7 Renal Impairment. United States. Source revised 7 August 2026. App review 27 August 2026. Regulatory product information.
- Hepatic impairment
- Hepatic dysfunction can substantially increase oxycodone exposure.
Population: Adults described in the cited product information
Applicability: United States
- Limitation: Product-specific evidence; do not transfer to other formulations.
- Oxycodone hydrochloride immediate-release tablet prescribing information8.6 Hepatic Impairment. United States. Source revised 7 August 2026. App review 27 August 2026. Regulatory product information.
OralModified-release tablet
App source review: 27 August 2026
View details and sources
Modified-release tablet
App source review: 27 August 2026
View details and sources- Peak concentration or effect
- Approximately 4.15 to 5.11 hours across strengths
Population: Adults described in the cited product information
Applicability: United States
- Limitation: Product-specific evidence; do not transfer to other formulations.
- OXYCONTIN extended-release tablet prescribing information12.3 Pharmacokinetics. United States. Source revised 24 June 2026. App review 27 August 2026. Regulatory product information.
- Elimination half-life
- 4.5 hours
Population: Adults described in the cited product information
Applicability: United States
- Limitation: Product-specific evidence; do not transfer to other formulations.
- OXYCONTIN extended-release tablet prescribing information12.3 Pharmacokinetics. United States. Source revised 24 June 2026. App review 27 August 2026. Regulatory product information.
- Steady state
- 24 to 36 hours
Population: Adults described in the cited product information
Applicability: United States
- Limitation: Product-specific evidence; do not transfer to other formulations.
- OXYCONTIN extended-release tablet prescribing information12.3 Pharmacokinetics. United States. Source revised 24 June 2026. App review 27 August 2026. Regulatory product information.
- Bioavailability
- 60% to 87%; relative bioavailability to immediate-release oxycodone is 100%
Population: Adults described in the cited product information
Applicability: United States
- Limitation: Product-specific evidence; do not transfer to other formulations.
- OXYCONTIN extended-release tablet prescribing information12.3 Pharmacokinetics. United States. Source revised 24 June 2026. App review 27 August 2026. Regulatory product information.
- Formulation behaviour
- Designed to deliver oxycodone over 12 hours.
Population: Adults described in the cited product information
Applicability: United States
- Limitation: Delivery interval is not proof of a precise clinical effect duration.
- OXYCONTIN extended-release tablet prescribing information12.3 Pharmacokinetics. United States. Source revised 24 June 2026. App review 27 August 2026. Regulatory product information.
- Receptor activity
- Full mu-opioid receptor agonist.
Population: Adults described in the cited product information
Applicability: United States
- Limitation: Product-specific evidence; do not transfer to other formulations.
- OXYCONTIN extended-release tablet prescribing information12.1 Mechanism of Action. United States. Source revised 24 June 2026. App review 27 August 2026. Regulatory product information.
- Metabolism
- CYP3A4 forms noroxycodone; CYP2D6 forms oxymorphone.
Population: Adults described in the cited product information
Applicability: United States
- Limitation: Product-specific evidence; do not transfer to other formulations.
- OXYCONTIN extended-release tablet prescribing information12.3 Pharmacokinetics. United States. Source revised 24 June 2026. App review 27 August 2026. Regulatory product information.
- Active metabolites
- Oxymorphone is active, but its contribution after oxycodone is considered clinically insignificant by the label.
Population: Adults described in the cited product information
Applicability: United States
- Limitation: Product-specific evidence; do not transfer to other formulations.
- OXYCONTIN extended-release tablet prescribing information12.3 Pharmacokinetics. United States. Source revised 24 June 2026. App review 27 August 2026. Regulatory product information.
- Elimination
- Oxycodone and metabolites are eliminated primarily in urine.
Population: Adults described in the cited product information
Applicability: United States
- Limitation: Product-specific evidence; do not transfer to other formulations.
- OXYCONTIN extended-release tablet prescribing information12.3 Pharmacokinetics. United States. Source revised 24 June 2026. App review 27 August 2026. Regulatory product information.
- Renal impairment
- Renal dysfunction increases oxycodone exposure and requires additional caution.
Population: Adults described in the cited product information
Applicability: United States
- Limitation: Product-specific evidence; do not transfer to other formulations.
- OXYCONTIN extended-release tablet prescribing information8.7 Renal Impairment. United States. Source revised 24 June 2026. App review 27 August 2026. Regulatory product information.
- Hepatic impairment
- Hepatic dysfunction can substantially increase oxycodone exposure.
Population: Adults described in the cited product information
Applicability: United States
- Limitation: Product-specific evidence; do not transfer to other formulations.
- OXYCONTIN extended-release tablet prescribing information8.6 Hepatic Impairment. United States. Source revised 24 June 2026. App review 27 August 2026. Regulatory product information.
OralOxycodone/naloxone modified-release tablet
App source review: 27 August 2026
View details and sources
Oxycodone/naloxone modified-release tablet
App source review: 27 August 2026
View details and sources- Bioavailability
- Oxycodone up to 87%; systemic naloxone availability below 3%
Population: Adults described in the cited product information
Applicability: Spain
- Limitation: Product-specific evidence; do not transfer to other formulations.
- TARGIN prolonged-release tablet SmPC5.2 Pharmacokinetic properties. Spain. Source revised 1 April 2025. App review 27 August 2026. Regulatory product information.
- Formulation behaviour
- Fixed oxycodone/naloxone combination for every-12-hour administration.
Population: Adults described in the cited product information
Applicability: Spain
- Limitation: Combination-product evidence must not be applied to oxycodone-only tablets.
- TARGIN prolonged-release tablet SmPC4.2 and 5.2. Spain. Source revised 1 April 2025. App review 27 August 2026. Regulatory product information.
- Receptor activity
- Oxycodone is an opioid agonist; naloxone is an opioid antagonist.
Population: Adults described in the cited product information
Applicability: Spain
- Limitation: Product-specific evidence; do not transfer to other formulations.
- TARGIN prolonged-release tablet SmPC5.1 Pharmacodynamic properties. Spain. Source revised 1 April 2025. App review 27 August 2026. Regulatory product information.
- Metabolism
- Oxycodone forms noroxycodone, oxymorphone and glucuronides.
Population: Adults described in the cited product information
Applicability: Spain
- Limitation: Product-specific evidence; do not transfer to other formulations.
- TARGIN prolonged-release tablet SmPC5.2 Pharmacokinetic properties. Spain. Source revised 1 April 2025. App review 27 August 2026. Regulatory product information.
- Elimination
- Oxycodone and metabolites are eliminated in urine and faeces.
Population: Adults described in the cited product information
Applicability: Spain
- Limitation: Product-specific evidence; do not transfer to other formulations.
- TARGIN prolonged-release tablet SmPC5.2 Pharmacokinetic properties. Spain. Source revised 1 April 2025. App review 27 August 2026. Regulatory product information.
- Renal impairment
- Exposure rises substantially in renal impairment.
Population: Adults described in the cited product information
Applicability: Spain
- Limitation: Product-specific evidence; do not transfer to other formulations.
- TARGIN prolonged-release tablet SmPC5.2 Pharmacokinetic properties. Spain. Source revised 1 April 2025. App review 27 August 2026. Regulatory product information.
- Hepatic impairment
- Moderate or severe hepatic impairment is contraindicated for this product.
Population: Adults described in the cited product information
Applicability: Spain
- Limitation: Product-specific evidence; do not transfer to other formulations.
- TARGIN prolonged-release tablet SmPC4.3 and 5.2. Spain. Source revised 1 April 2025. App review 27 August 2026. Regulatory product information.
ParenteralDefault in appSubcutaneous injection
App source review: 27 August 2026
View details and sources
Subcutaneous injection
App source review: 27 August 2026
View details and sources- Peak concentration or effect
- Subcutaneous plasma peak at approximately 0.5 hour
Population: Adults described in the cited product information
Applicability: United Kingdom
- Limitation: Product-specific evidence; do not transfer to other formulations.
- Oxycodone 10 mg/mL solution for injection or infusion SmPC5.2 Pharmacokinetic properties. United Kingdom. Source revised 25 April 2024. App review 27 August 2026. Regulatory product information.
- Elimination half-life
- Approximately 3 hours
Population: Adults described in the cited product information
Applicability: United Kingdom
- Limitation: Product-specific evidence; do not transfer to other formulations.
- Oxycodone 10 mg/mL solution for injection or infusion SmPC5.2 Pharmacokinetic properties. United Kingdom. Source revised 25 April 2024. App review 27 August 2026. Regulatory product information.
- Receptor activity
- Full mu-opioid receptor agonist.
Population: Adults described in the cited product information
Applicability: United Kingdom
- Limitation: Product-specific evidence; do not transfer to other formulations.
- Oxycodone 10 mg/mL solution for injection or infusion SmPC5.1 Pharmacodynamic properties. United Kingdom. Source revised 25 April 2024. App review 27 August 2026. Regulatory product information.
- Metabolism
- CYP3A4 and CYP2D6 form noroxycodone and oxymorphone.
Population: Adults described in the cited product information
Applicability: United Kingdom
- Limitation: Product-specific evidence; do not transfer to other formulations.
- Oxycodone 10 mg/mL solution for injection or infusion SmPC5.2 Pharmacokinetic properties. United Kingdom. Source revised 25 April 2024. App review 27 August 2026. Regulatory product information.
- Active metabolites
- Oxymorphone is active, but its contribution after oxycodone is limited.
Population: Adults described in the cited product information
Applicability: United Kingdom
- Limitation: Product-specific evidence; do not transfer to other formulations.
- Oxycodone 10 mg/mL solution for injection or infusion SmPC5.2 Pharmacokinetic properties. United Kingdom. Source revised 25 April 2024. App review 27 August 2026. Regulatory product information.
- Elimination
- Oxycodone and metabolites are eliminated in urine and faeces.
Population: Adults described in the cited product information
Applicability: United Kingdom
- Limitation: Product-specific evidence; do not transfer to other formulations.
- Oxycodone 10 mg/mL solution for injection or infusion SmPC5.2 Pharmacokinetic properties. United Kingdom. Source revised 25 April 2024. App review 27 August 2026. Regulatory product information.
- Renal impairment
- Exposure increases in renal impairment.
Population: Adults described in the cited product information
Applicability: United Kingdom
- Limitation: Product-specific evidence; do not transfer to other formulations.
- Oxycodone 10 mg/mL solution for injection or infusion SmPC5.2 Pharmacokinetic properties. United Kingdom. Source revised 25 April 2024. App review 27 August 2026. Regulatory product information.
- Hepatic impairment
- Exposure increases in hepatic impairment.
Population: Adults described in the cited product information
Applicability: United Kingdom
- Limitation: Product-specific evidence; do not transfer to other formulations.
- Oxycodone 10 mg/mL solution for injection or infusion SmPC5.2 Pharmacokinetic properties. United Kingdom. Source revised 25 April 2024. App review 27 August 2026. Regulatory product information.
ParenteralIntravenous injection
App source review: 27 August 2026
View details and sources
Intravenous injection
App source review: 27 August 2026
View details and sources- Elimination half-life
- Approximately 3 hours
Population: Adults described in the cited product information
Applicability: United Kingdom
- Limitation: Product-specific evidence; do not transfer to other formulations.
- Oxycodone 10 mg/mL solution for injection or infusion SmPC5.2 Pharmacokinetic properties. United Kingdom. Source revised 25 April 2024. App review 27 August 2026. Regulatory product information.
- Receptor activity
- Full mu-opioid receptor agonist.
Population: Adults described in the cited product information
Applicability: United Kingdom
- Limitation: Product-specific evidence; do not transfer to other formulations.
- Oxycodone 10 mg/mL solution for injection or infusion SmPC5.1 Pharmacodynamic properties. United Kingdom. Source revised 25 April 2024. App review 27 August 2026. Regulatory product information.
- Metabolism
- CYP3A4 and CYP2D6 form noroxycodone and oxymorphone.
Population: Adults described in the cited product information
Applicability: United Kingdom
- Limitation: Product-specific evidence; do not transfer to other formulations.
- Oxycodone 10 mg/mL solution for injection or infusion SmPC5.2 Pharmacokinetic properties. United Kingdom. Source revised 25 April 2024. App review 27 August 2026. Regulatory product information.
- Active metabolites
- Oxymorphone is active, but its contribution after oxycodone is limited.
Population: Adults described in the cited product information
Applicability: United Kingdom
- Limitation: Product-specific evidence; do not transfer to other formulations.
- Oxycodone 10 mg/mL solution for injection or infusion SmPC5.2 Pharmacokinetic properties. United Kingdom. Source revised 25 April 2024. App review 27 August 2026. Regulatory product information.
- Elimination
- Oxycodone and metabolites are eliminated in urine and faeces.
Population: Adults described in the cited product information
Applicability: United Kingdom
- Limitation: Product-specific evidence; do not transfer to other formulations.
- Oxycodone 10 mg/mL solution for injection or infusion SmPC5.2 Pharmacokinetic properties. United Kingdom. Source revised 25 April 2024. App review 27 August 2026. Regulatory product information.
- Renal impairment
- Exposure increases in renal impairment.
Population: Adults described in the cited product information
Applicability: United Kingdom
- Limitation: Product-specific evidence; do not transfer to other formulations.
- Oxycodone 10 mg/mL solution for injection or infusion SmPC5.2 Pharmacokinetic properties. United Kingdom. Source revised 25 April 2024. App review 27 August 2026. Regulatory product information.
- Hepatic impairment
- Exposure increases in hepatic impairment.
Population: Adults described in the cited product information
Applicability: United Kingdom
- Limitation: Product-specific evidence; do not transfer to other formulations.
- Oxycodone 10 mg/mL solution for injection or infusion SmPC5.2 Pharmacokinetic properties. United Kingdom. Source revised 25 April 2024. App review 27 August 2026. Regulatory product information.
ParenteralContinuous parenteral infusion
App source review: 27 August 2026
View details and sources
Continuous parenteral infusion
App source review: 27 August 2026
View details and sourcesRectalDefault in app30 mg rectal suppository
App source review: 27 August 2026
View details and sources
30 mg rectal suppository
App source review: 27 August 2026
View details and sources- Onset
- Analgesic onset 0.5 to 1 hour
Population: 12 adults with moderate to severe cancer pain
Applicability: International primary study
- Limitation: Small primary study of a 30 mg rectal suppository; substantial between-person variability.
- Pharmacokinetics and pharmacodynamics of intravenous and rectal oxycodone in adult cancer painResults. International primary study. Source revised 1 January 1995. App review 27 August 2026. Primary study.
- Duration
- Approximately 8 to 12 hours
Population: 12 adults with moderate to severe cancer pain
Applicability: International primary study
- Limitation: Small primary study; do not generalise to other rectal products or doses.
- Pharmacokinetics and pharmacodynamics of intravenous and rectal oxycodone in adult cancer painResults. International primary study. Source revised 1 January 1995. App review 27 August 2026. Primary study.
- Bioavailability
- Mean 61.6%, standard deviation 30.2%
Population: 12 adults with moderate to severe cancer pain
Applicability: International primary study
- Limitation: Very wide variability in a small primary study.
- Pharmacokinetics and pharmacodynamics of intravenous and rectal oxycodone in adult cancer painResults. International primary study. Source revised 1 January 1995. App review 27 August 2026. Primary study.
- Formulation behaviour
- The Australian consumer medicine information states that the suppository takes about one hour to be completely absorbed and work.
Population: Adults described in the cited product information
Applicability: Australia
- Limitation: Consumer medicine information; the primary study supplies the quantitative PK evidence.
- Proladone consumer medicine informationSection 4. Australia. Source revised 5 December 2025. App review 27 August 2026. Regulatory product information.
Sources used on this page
- Oxycodone hydrochloride immediate-release tablet prescribing informationUnited States. Revision date 7 August 2026.
- OXYCONTIN extended-release tablet prescribing informationUnited States. Revision date 24 June 2026.
- TARGIN prolonged-release tablet SmPCSpain. Revision date 1 April 2025.
- Proladone consumer medicine informationAustralia. Revision date 5 December 2025.
- Pharmacokinetics and pharmacodynamics of intravenous and rectal oxycodone in adult cancer painInternational primary study. Revision date 1 January 1995.
- Oxycodone 10 mg/mL solution for injection or infusion SmPCUnited Kingdom. Revision date 25 April 2024.
Other medicine references
Use the full calculator
Compare opioid regimens and inspect formulation-specific information in OpioidCalc for iOS and Android.